Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

86.60 -0.52 (-0.60%)
Official Closing Price Updated: 7:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
RJK Jr.'s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing
Robert F. Kennedy Jr., HHS secretary nominee, faces criticism for financial ties to vaccine lawsuits, raising ethical concerns over regulatory impartiality. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals. 
Via Chartmill
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%
Via The Motley Fool
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target. 
Via Benzinga
Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines
Ellison, Oracle's chairman, pointed to the use of AI to develop drugs like Moderna's cancer vaccine. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Price Over Earnings Overview: Merck & Co
Via Benzinga
Unpacking the Latest Options Trading Trends in Merck & Co
Via Benzinga
Is NYSE:MRK suited for dividend investing?
Uncovering Dividend Opportunities with MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
Why Summit Therapeutics Stock Is Jumping Today
Via The Motley Fool
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Earnings Season Scorecard And Fresh Analyst Reports For Chevron, Merck & Others
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation, Merck & Co., Inc., and QUALCOMM Incorporated, as well as two micro-cap stocks CSP Inc. and AMCON... 
Via Talk Markets
Topics Stocks / Equities
Healthcare And Biotech Stocks Lag The Market Again
Biotech stocks got little help from the JPM Conference despite some recovery to the general market. 
Via Talk Markets
Topics Stocks / Equities
AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion
Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market,... 
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Exposures Artificial Intelligence
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4
From Merck & Co., Inc.
Via Business Wire
3 Magnificent S&P 500 Dividend Stocks Down 25%, 60%, and 26% to Buy and Hold Forever
The time to step into quality dividend payers is when the crowd forgets there's never a bad time to own a high-quality stock. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
What Lies Ahead In 2025? Slower Growth, More Volatility
As we move through 2025, the global economy and financial markets are facing a critical juncture. 
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Economy
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?
Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025. 
Via Investor's Business Daily
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. 
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Moderna Shares Spike on H5N1 News—What’s Next for Investors?
MRNA stock surged over 12% on growing bird flu concerns; that rally may not last, but analysts believe the company's pipeline makes the stock a Buy in 2025 
Via MarketBeat
Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Merck’s GARDASIL® Receives Expanded Approval for Males in China
From Merck & Co., Inc.
Via Business Wire
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments. 
Via Benzinga
Merck Buys WuXi Vaccines' Irish Manufacturing Facility For Over $500 Million
MSD acquires WuXi Vaccines' Dundalk facility with a €500 million investment, creating 1,000 new jobs across Ireland and expanding its vaccine production capabilities. 
Via Benzinga
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights. 
Via Benzinga
Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Why Viking Therapeutics Stock Plummeted by 24% in December
Via The Motley Fool
Should You Buy the Dip on This High-Flying Stock?
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS